All of this begs the question of whether we are any closer to finding a pill we can offer to people to increase longevity. The data so far don’t seem promising, especially if it’s true that many of the mechanisms that underlie ageing are defences against developing cancer. There’s not a lot of point creating therapies that could allow us to live for another 50 years, if they also lead to tumours that could kill us in five. But there is one way of increasing lifespan that has proven astonishingly effective, from yeast to fruit flies, from worms to mammals. This is calorie restriction.
If you only give rodents about 60 per cent of the calories they would eat if given free access to food, there is a dramatic impact on longevity and development of age-related diseases[250]
. The restricted calorie intake must start early in life and be continued throughout life to see this effect. In yeast, decreasing the amount of glucose (fuel) in the culture from 2 per cent to 0.5 per cent extended the lifespan by around 30 per cent[251].There’s been a lot of debate on whether or not this calorie-restriction effect is mediated via sirtuins, such as Sir2 in yeast, or the versions of Sir2 in other animals. Sir2 is regulated in part by a key chemical, whose levels are affected by the amount of nutrition available to cells. That’s the reason why some authors have suggested that the two might be connected, and it’s an attractive hypothesis. There’s no debate that Sir2 is definitely important for longevity. Calorie restriction is also clearly very important. The question is whether the two work together or separately. There’s no consensus as yet on this, and the experimental findings are very influenced by the model system used. This can come down to details that at first glance might almost seem trivial, such as which strain of brewer’s yeast is used, or exactly how much glucose is in the culture liquid.
The question of how calorie restriction works might seem much less important than the fact that it does. But the mechanism matters enormously if we’re looking for an anti-ageing strategy, because calorie restriction has severe limitations for humans. Food has enormous social and cultural aspects, it’s rarely just fuel for us. In addition to these psychological and sociological issues, calorie restriction has side effects. The most obvious ones are muscle wasting and loss of libido. It’s not much of a surprise that when offered the chances of living longer, but with these side-effects, the majority of people find the prospect unattractive[252]
.That’s one of the reasons that a 2006 paper in
Professor Sinclair and his colleagues raised mice on very high calorie diets, and treated the mice with resveratrol for six months. At the end of this six-month period, they examined all sorts of health outcomes in the mice. All the mice which had been on the high calorie diets were fat, regardless of whether or not they had been treated with resveratrol. But the mice treated with resveratrol were healthier than the untreated fat mice. Their livers were less fatty, their motor skills were better, they had fewer diabetes symptoms. By the age of 114 weeks, the resveratrol-treated mice had a 31 per cent lower death rate than the untreated animals fed the same diet[255]
.We can see immediately why this paper garnered so much attention. If the same effects could be achieved in humans, resveratrol would be a get-out-of-obesity-free card. Eat as much as you like, get as fat as you want and yet still have a long and healthy life. No leaving behind one-third of every meal and losing your muscles and your libido.
How was resveratrol doing this? A previous paper from the same group showed that resveratrol activated a sirtuin protein, in this case Sirt1[256]
. Sirt1 is believed to be important for the control of sugar and fat metabolism.Professor Sinclair set up a company called Sirtris Pharmaceuticals, which continued to make new compounds based around the structure of resveratrol. In 2008 GlaxoSmithKline paid $720 million for Sirtris Pharmaceuticals to gain access to its expertise and portfolio of compounds for treating diseases of ageing.